Wedbush Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $26.00

Vera Therapeutics (NASDAQ:VERA) had its price objective trimmed by Wedbush from $34.00 to $26.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a neutral rating on the stock. Wedbush also issued estimates for Vera Therapeutics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($3.23) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($3.14) EPS, FY2028 earnings at ($2.13) EPS and FY2029 earnings at $0.81 EPS.

Several other brokerages have also recently weighed in on VERA. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. Guggenheim boosted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. HC Wainwright assumed coverage on Vera Therapeutics in a report on Monday, May 5th. They issued a “buy” rating and a $75.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Cantor Fitzgerald lowered their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $63.80.

Vera Therapeutics Stock Down 1.2 %

Shares of NASDAQ VERA opened at $21.77 on Wednesday. The firm has a 50 day moving average price of $24.22 and a 200 day moving average price of $34.72. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a market cap of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period last year, the business posted ($0.56) EPS. Analysts expect that Vera Therapeutics will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Huntington National Bank bought a new position in Vera Therapeutics in the 4th quarter valued at approximately $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the fourth quarter worth $34,000. GF Fund Management CO. LTD. acquired a new stake in Vera Therapeutics in the fourth quarter valued at $56,000. KBC Group NV lifted its holdings in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the period. Finally, Summit Investment Advisors Inc. grew its position in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock valued at $196,000 after buying an additional 639 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.